Recurrent Disease Active Not Recruiting Phase 2 Trials for Nilotinib (DB04868)

IndicationStatusPhase
DBCOND0028541 (Recurrent Disease)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00036738Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or NilotinibTreatment